Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022
May 02 2022 - 4:05PM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the
“Company”) today announced that it will release financial and
operational results for first quarter 2022 on Tuesday, May 10,
2022, before markets open. Aurinia’s management team will host a
conference call/webcast at 8:30 am ET that day to review these
results and provide a general business update.
Interested participants can dial +1-877-407-9170 (Toll-free U.S.
& Canada). The audio webcast can also be accessed under
"News/Events” through the “Investors” section of the Aurinia
corporate website at www.auriniapharma.com. A replay of the webcast
will be available on Aurinia’s website.
About Aurinia
Aurinia is a fully integrated biopharmaceutical company focused
on delivering therapies to treat targeted patient populations that
are impacted by serious diseases with a high unmet medical need. In
January 2021, the Company introduced the first FDA-approved oral
therapy indicated for the treatment of adult patients with active
lupus nephritis (LN). Aurinia’s head office is in Victoria, British
Columbia; its U.S. commercial hub is in Rockville, Maryland; and
the Company focuses development efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220502005587/en/
Investor and Corporate Dana Lynch, IR & Corporate
Communications dlynch@auriniapharma.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2023 to Apr 2024